Background and aim: An algorithm based on a 2 log10 decline of HCV RNA at week (W) 12 has been proposed in US and European recommendations for the management of patients with chronic hepatitis C treated with pegylated- interferon and ribavirin.
Methods: We have studied rapid virological response (RVR, i.e. at W2 and W4 after the initiation of therapy) in HIV/HCV co-infected patients. Using HCV RNA measurements (Versant® HCV RNA 3.0, Cobas Amplicor HCV 2.0), RVR was studied in 323 patients from the ANRS HC02 RIBAVIC trial, comparing Interferon α2b 3 MU x3/week versus Pegylated Interferon α2b 1.5 μg/kg/week, each combined with ribavirin 800 mg/day during 48 weeks.
Results: The best positive and negative predictive values of sustained virological response (SVR) were respectively obtained with an undetectable HCV RNA at W4 (97%) and with more than a 2 log10 decrease at W12 (99%). Prediction of non-SVR was obtained in all patients by using HCV RNA cutoff levels above 460,000 IU/ml at W4 and above 39,000 UI/ml at W12 whatever the HCV genotype and arm of treatment.
Conclusion: We propose a new algorithm based on RVR thresholds using HCV RNA that allows for excellent prediction of non-SVR as early as W4.
- HCV viral load
- HIV/HCV coinfection
- hepatitis C therapy
- prediction of response
- rapid and early viral decline
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.